SEC Form 4 · accession 0001209191-17-054196
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David D Chang
Officer — EVP, R&D, Chief Medical Off.
Period of report
Sep 25, 2017
Accepted (ET)
Sep 27, 2017 · 9:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 25, 2017 | A | 15,000 | $0.00 | A | 65,350 | D | |
| Common Stock | Sep 25, 2017 | S | 7,927 | $179.6639 | D | 57,423 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 185 shares acquired under the 2014 Employee Stock Purchase Plan on August 18, 2017.
- F2The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.